Combined use of luteolin (5 to 10 μM) and mTOR inhibitor rapamycin (100 nM) prevented low doses of luteolin from inducing p21 expression, and HER2/neu-overexpressing cancer cells would be sensitized toward luteolin-induced apoptosis. Here, ERBB2 is linked to cancer.